Low-dose eplerenone decreases left ventricularmass in treatment-resistant hypertension

Journal of Hypertension

Volumn 35, Issue 5, 2017, Pages 1086-1092

  Schneider, Andreas ^a,b   Schwab, Johannes ^c   Karg, Marina V ^b   Kalizki, Tatjana ^b   Reinold, Annemarie ^b   Schneider, Markus P ^b   Schmieder, Roland E ^b   Schmidt, Bernhard M W ^d  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Aldosterone; Hypertension; Left ventricular hypertrophy

Indexed keywords

EPLERENONE; PLACEBO; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; COMBINATION DRUG THERAPY; COMPLICATION; CORONARY VASOSPASM; DIAGNOSTIC IMAGING; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY VASOSPASM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 85010868269     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001264     Document Type: Article

References (18)

1. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40:23-27.
2. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16:80-86.
3. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
4. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3:486-492.
5. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-845.
6. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386:2059-2068.
7. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069-1075.
8. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108:1831-1838.
9. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011; 4:1239-1249.
10. Bozzali M, Falini A, Cercignani M, Baglio F, Farina E, Alberoni M, et al. Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain 2005; 128 (Pt 7):1595-1604.
11. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52:559-566.
12. Yeon SB, Salton CJ, Gona P, Chuang ML, Blease SJ, Han Y, et al. Impact of age, sex, and indexation method on MR left ventricular reference values in the Framingham Heart Study offspring cohort. J Magn Reson Imaging 2015; 41:1038-1045.
13. Armstrong AC, Jacobs DR Jr, Gidding SS, Colangelo LA, Gjesdal O, Lewis CE, et al. Framingham score and LV mass predict events in young adults: CARDIA study. Int J Cardiol 2014; 172:350-355.
14. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
15. Waanders F, de Vries LV, van Goor H, Hillebrands JL, Laverman GD, Bakker SJ, et al. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. Curr Vasc Pharmacol 2011; 9:594-605.
16. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26:671-677.
17. Boscaro M, Giacchetti G, Ronconi V. Visceral adipose tissue: emerging role of gluco-and mineralocorticoid hormones in the setting of cardiometabolic alterations. Ann N Y Acad Sci 2012; 1264:87-102.
18. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004; 110:1263-1268.